Profitelligence Profitelligence · Filing Ledger Open RVTY research →

Form 8-K · Current Report · Filed 2026-05-01

Revvity, Inc. Shareholders Approve Key By-law Amendments

On April 28, 2026, Revvity, Inc. shareholders approved several key proposals at the annual meeting, including amendments to the company's by-laws to allow shareholders owning 25% of the company's stock to call a special meeting of shareholders. The shareholders also elected ten nominees for director, ratified the selection of Deloitte & Touche LLP as the independent public accounting firm, and approved the company's executive compensation by non-binding advisory vote. A shareholder proposal regarding executive stock ownership was not approved.

Filer
Revvity Inc. RVTY · NYSE
Filed
Accession
0001193125-26-201401
CIK
0000031791
Signal
Medium impactHealthcare

Items reported

Item events

Reported Item

Bylaw Amendment Board Member Appointed Auditor Resignation General Statement

Market reaction

Close before filing

$86.62

Next session

-0.1%

Since filing

+69.4%

Latest close

$146.73

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from RVTY reporting the same item, with the next session's move:

Revvity, Inc. Announces Financial Results for Q4 and Full Year 2025-7.0%
Revvity Announces Preliminary Q4 2025 Results and Upcoming J.P. Morgan Presentation+7.3%

About Revvity Inc.

Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another RVTY filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts